Revive Therapeutics Ltd (RVV)

0.195
+0.020(+8.33%)
  • Volume:
    40,000
  • Bid/Ask:
    0.000/0.000
  • Day's Range:
    0.175 - 0.195
Earnings results expected tomorrow

Revive Therapeutics will announce its quarterly financial results tomorrow. Traders should take this into account as the share price often fluctuates around this time period.

RVV Overview

Prev. Close
0.18
Day's Range
0.175-0.195
Revenue
-
Open
0.175
52 wk Range
0.155-0.56
EPS
-0.07
Volume
40,000
Market Cap
64.23M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
36,828
P/E Ratio
-
Beta
-0.38
1-Year Change
-60.61%
Shares Outstanding
321,127,951
Next Earnings Date
Nov 30, 2022
What is your sentiment on Revive Therapeutics?
or
Market is currently closed. Voting is open during market hours.

Revive Therapeutics Ltd News

Revive Therapeutics Ltd Analysis

Revive Therapeutics Ltd Company Profile

Revive Therapeutics Ltd Company Profile

Employees
2
Market
Canada
  • Type:Equity
  • Market:Canada
  • ISIN:CA7615161030
  • CUSIP:761516103

Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics for rare disorders and infectious diseases. The company offers cannabinoid pharmaceutical portfolio that focuses on rare inflammatory diseases. It is developing Bucillamine, which is in Phase 3 clinical study for the treatment of infectious diseases, including influenza and COVID-19; Psilocybin that is in Phase 1 clinical study for treating methamphetamine use disorder; Psilocin for the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and other diseases; and cannabidiol for treating autoimmune hepatitis and ischemia and reperfusion injury from organ transplantation. Revive Therapeutics Ltd. has research collaboration agreements with PharmaTher Inc. for the development of psilocybin in the treatment of cancer and the discovery of other uses of undisclosed psychedelic compounds; North Carolina State University for the development of a biosynthetic version of psilocybin based on a natural biosynthesis enzymatic platform; the University of California, San Francisco to explore the use of Bucillamine as a treatment for severe COVID-19; University of Health Sciences Antigua for the clinical research of psychedelics; and PharmaTher for the development of psilocybin microneedle patch. The company was incorporated in 2012 and is headquartered in Toronto, Canada.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyBuyNeutralSellStrong Sell
Technical IndicatorsStrong BuyStrong BuyBuyStrong SellStrong Sell
SummaryStrong BuyStrong BuyNeutralStrong SellStrong Sell
  • Hold
    0
    • No selling
      0
      • 50% day love it
        0
        • a bargain. thank you all
          0
      • fun stuff
        0
        • they just bought some Psilocybin related research
          0
          • noice
            0
            • whats the deal here?
              0
              • hoping for a big week !
                0
                • Mary joy what u think ACDC
                  0
                  • babar abhasi, i hope u already bought nio
                    0
                    • no brother i miss it
                      0